Pipeline Acquisitions, Co-Promotion Deals, To Drive Ipsen
Business Efficiencies Also Targeted By Management
Ipsen’s business strategy calls for accessing external innovation across its pipeline, combined with geographic expansion, realizing the unmet potential of its marketed products and business efficiencies in manufacturing and operations.
You may also be interested in...
Genentech will use the X-Chem platform to obtain leads against multiple oncology targets. Lilly partners with Merus on CD3-targeting T-cell therapy candidates.
Despite concerns over toxicity due to early growth plate closure in skeletally immature patients, Ipsen's CEO David Loew is confident that palovarotene will get through regulatory review for fibrodysplasia ossificans progressive.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.